Biosimilars are biological compounds, almost identical to a reference biologic drug that have been approved by the U.S. Food and Drug Administration for medical treatment. Research-grade biosimilars are research tools for analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.
Challenge in biosimilar research: One of the critical challenges in analyzing impact of biosimilars is getting a validated positive control for in-situ analysis. It is especially challenging when these projects involve mutant proteins. Not only is the sample inconsistent in staining but are in short supply.
CytoSections are FFPE sections of HEK293T cell pellet that over-expresses targeted proteins. These cells are obtained by transfection of a sequenced verified cDNA clones transfected into HEK293T cells and the expression is verified by western blot and IHC analysis. Learn more about CytoSections here.
List of other tools for biosimilar research: